The U.S. Department of Health and Human Services is moving to fast-track early-stage drug development with a new blueprint aimed at reducing the burden on biotech and improving access to clinical trials. The plan includes efforts to clarify data expectations before Investigational New Drug (IND) filings and to make trial protocols more flexible to limit repetitive amendments. HHS also plans to pilot a consult process that lets developers work with a network of research institutions during IND preparation. A rolling submission platform is proposed to provide timely guidance based on institutional recommendations. The initiative comes amid intensified concern about U.S. trial timelines and costs as developers consider China and other jurisdictions for early proof-of-concept studies. The blueprint also raises questions about trial-enrollee stipends under federal anti-kickback law constraints.